{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:50:41Z","timestamp":1773204641571,"version":"3.50.1"},"reference-count":46,"publisher":"Wiley","issue":"5-6","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":602,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2000,5]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1. Amylin is a pancreatic peptide that has been shown to be able to induce a state of peripheral insulin resistance. Hyperamylinaemia, which occurs in type 2 diabetes, may be central to a number of metabolic abnormalities present in the diabetic state. Because lipoprotein metabolism is often disturbed in diabetes, we investigated whether amylin was a regulating factor of lipoprotein metabolism in rats; specifically, whether exogenous amylin influences production and clearance of triglyceride (TG)\u2010rich lipoproteins.<\/jats:p><jats:p>2. When amylin was given acutely to rats or by way of infusion, total plasma TG was significantly elevated. Acute doses of amylin decreased fractional clearance rates of TG\u2010rich lipoproteins by 45%. Hydrolysis of lipoproteins by endothelial lipases was not decreased; rather, amylin appeared to reduce hepatic uptake of TG\u2010rich lipoproteins, following conversion to the remnant form. Consistent with the kinetic data <jats:italic>in vivo<\/jats:italic>, cell culture studies found that amylin reduced the high\u2010affinity uptake of remnant lipoproteins, probably by inhibiting low\u2010density lipoprotein receptor expression.<\/jats:p><jats:p>3. We have found that amylin can influence the kinetics of TG\u2010rich lipoproteins <jats:italic>in vivo<\/jats:italic> and <jats:italic>in vitro<\/jats:italic>. Amylin can reduce chylomicron uptake, most probably by regulating lipoprotein receptors either directly, or via modulation of insulin activity. Increased levels of amylin in type 2 diabetes may contribute to the raised concentration of TG\u2010rich remnant lipoproteins present in this disease.<\/jats:p>","DOI":"10.1046\/j.1440-1681.2000.03255.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T11:06:32Z","timestamp":1047380792000},"page":"345-351","source":"Crossref","is-referenced-by-count":8,"title":["Islet Amyloid Polypeptide (Amylin) Modulates Chylomicron Metabolism In Rats"],"prefix":"10.1111","volume":"27","author":[{"given":"D","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jcl","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","unstructured":"SteinerG.Diabetes and atherosclerosis: An overview.Diabetes1981;30(Suppl. 2): 1\u20137.","DOI":"10.2337\/diab.30.2.S1"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","unstructured":"ReavenGM&GreenfieldMS.Diabetic hypertriglyceridemia: Evidence for three clinical syndromes.Diabetes1981;30(Suppl. 2): 66\u201375.","DOI":"10.2337\/diab.30.2.S66"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0022-2275(20)38659-4","article-title":"Lipid metabolism in diabetes mellitus.","volume":"28","author":"Howard BV.","year":"1987","journal-title":"J. Lipid Res."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00274772"},{"key":"e_1_2_6_6_2","first-page":"195","article-title":"Endothelial heterogeneity and intimal blood\u2010borne cells. Relation to human atherosclerosis.","volume":"454","author":"Romanov YA","year":"1995","journal-title":"Ann. NY Acad. Sci."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-199408000-00008"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","unstructured":"SteinerG&LewisGF.Hyperinsulinemia and triglyceride\u2010rich lipoproteins.Diabetes1996;45(Suppl. 3): S24\u20136.","DOI":"10.2337\/diab.45.3.S24"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(90)90058-6"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(95)90193-0"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(74)90006-0"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1997.tb01822.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(05)81133-7"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/335632a0"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(89)90220-6"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.23.8628"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.41.8.975"},{"key":"e_1_2_6_18_2","first-page":"13","article-title":"No measurable effect of amylin on lipolysis in either white or brown isolated adipocytes from rats.","volume":"6","author":"Lupien JR","year":"1993","journal-title":"Diabetes Nutr. Metab."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(94)90076-0"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2760381"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.13.2.231"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(75)90488-1"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2760(97)00033-7"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1042\/bj2860937","article-title":"Clearance from plasma of lymph chylomicrons remnants labelled with 125I\u2010tyramine\u2010 cellobiose.","volume":"286","author":"Ly HL","year":"1992","journal-title":"Biochem. J."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi960188s"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.3177\/jnsv.36.4-SupplementI_399"},{"key":"e_1_2_6_27_2","first-page":"G709","article-title":"Kinetics and uptake in vivo of oxidatively modified lymph chylomicrons.","volume":"268","author":"Umeda Y","year":"1995","journal-title":"Am. J. Physiol."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1967.sp008211"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj1560539"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(91)92078-X"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/07435809209111040"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90480-Q"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0022-2275(20)34342-X","article-title":"Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride\u2010rich lipoproteins and their remnants by the perfused liver.","volume":"26","author":"Windler E","year":"1985","journal-title":"J. Lipid Res."},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.50.31348"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(90)90015-4"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.20.7763"},{"key":"e_1_2_6_37_2","doi-asserted-by":"crossref","unstructured":"LeightonBC DaCostaC FootE.Effect of synthetic human amylin on glycogen synthesis in skeletal musclein vivo.Biochem. Soc. Trans.1990;18: 980.","DOI":"10.1042\/bst0180980"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2690019"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmr.5610030206"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(92)90298-A"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(91)91855-7"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)80222-3"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040408"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114900"},{"key":"e_1_2_6_45_2","first-page":"325","article-title":"Insulin increases triglyceride secretion rate in rats in vivo.","volume":"11","author":"Satoh S","year":"1987","journal-title":"Int. J. Obesity"},{"key":"e_1_2_6_46_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/cs0880007","article-title":"A reappraisal of current hypotheses concerning the possible roles of amylin in physiology, pathology and therapeutics.","volume":"88","author":"Cooper GJS.","year":"1995","journal-title":"Clin. Sci."},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-15-2-163"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1681.2000.03255.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1681.2000.03255.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:15:38Z","timestamp":1693480538000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1681.2000.03255.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":46,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["10.1046\/j.1440-1681.2000.03255.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1681.2000.03255.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}